Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 255

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 255
---
ienne Lecorvaisier (independent director)                                                | Carole Ferrand (independent director)(b)                                                                                                                 |
| Members         | Christophe Babule(a)Carole Ferrand (independent director)Diane Souza (independent director) | Christophe Babule(a)Clotilde Delbos (independent director)(c)Fabienne Lecorvaisier (independent director)Anne-Françoise Nesmes (independent director)(c) |
|                 | Proportion of independent directors: 75% (3/4)                                              | Proportion of independent directors: 80% (4/5)                                                                                                           |

(a) This table only refers to independence as defined under the AFEP-MEDEF Code. However, Christophe Babule is independent for the purposes of the NASDAQ Listing Rules and Rule 10A-3 under the Exchange Act. (b) Carole Ferrand was appointed as Chair of the Audit Committee by a Board decision of April 30, 2024 to facilitate the handover with Fabienne Lecorvaisier, whose term of office as member of the board and Chair of the Audit Committee will expire at the close of the Annual General Meeting called to approve the financial statements for the year ended December 31, 2024. (c) Clotilde Delbos and Anne-Françoise Nesmes were appointed members of the Audit Committee by a Board decision of April 30, 2024. All members of the Audit Committee have financial or accounting expertise as a consequence of their training and professional experience, and all are deemed to be financial experts as defined by the Sarbanes-Oxley Act and by Article L. 823-19 of the French Commercial Code. See “Item 16A. Audit Committee Financial Expert”. Remit of the Committee The remit of the Committee is described in our Board Charter, provided as Exhibit 1.2 to this annual report . Since December 2023, our Audit Committee has been tasked with reviewing the process for the preparation and certification of sustainability disclosures. In fulfilling that role, the Audit Committee works in conjunction with the Appointments, Governance and CSR Committee. Collectively, the two committees determined the material sustainability issues facing Sanofi. Operation of the Committee In addition to the statutory auditors, the principal financial officers, the Senior Vice President Group Internal Audit and other members of the senior management team attend meetings of the Audit Committee. The statutory auditors attend all meetings of the Audit